Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment

被引:8
|
作者
Lobetti-Bodoni, Chiara [1 ]
Ferrero, Dario [1 ]
Genuardi, Elisa [1 ]
Passera, Roberto
Bernocco, Elisa [1 ]
Sia, Daniela [2 ]
Grignani, Giovanni [3 ]
Crisa, Elena [1 ]
Monitillo, Luigia [1 ]
Rocci, Alberto [1 ]
Drandi, Daniela [1 ]
Giai, Valentina [1 ]
Zanni, Manuela [1 ]
Boi, Michela [1 ]
Isaia, Gianluca [4 ]
Barbero, Daniela [1 ]
Lunghi, Monia [5 ]
Abruzzese, Elisabetta [6 ]
Radaelli, Franca [7 ]
Pini, Massimo [8 ]
Pregno, Patrizia [9 ]
Carlo-Stella, Carmelo [2 ]
Gaidano, Gianluca [5 ]
Boccadoro, Mario [1 ]
Ladetto, Marco [1 ]
机构
[1] Univ Turin, Div Hematol, AOU San Giovanni Battista, Turin, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] Inst Canc Res & Treatment IRCC, Med Oncol Unit, Candiolo, Italy
[4] Univ Turin, Dept Med & Surg, Geriatr Sect, Turin, Italy
[5] Amedeo Avogadro Univ Eastern Piedmont, Dept Clin & Expt Med, Div Hematol, Novara, Italy
[6] Tor Vergata Univ Hosp, Dept Hematol, Rome, Italy
[7] Fdn IRCCS Policlin, Milan, Italy
[8] AO SS Antonio & Biagio, Div Hematol, Alessandria, Italy
[9] AOU San Giovanni Battista, Div Hematol 2, Turin, Italy
关键词
Telomere shortening; Cytogenetic abnormalities; Bone marrow failure; Tyrosine kinase inhibitors; Hematopoiesis; IMATINIB MESYLATE THERAPY; CLONAL CYTOGENETIC ABNORMALITIES; CHRONIC MYELOGENOUS LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; CHROMOSOMAL-ABNORMALITIES; POLYCLONAL HEMATOPOIESIS; CELLULAR SENESCENCE; CHRONIC-PHASE; DNA-DAMAGE; STEM-CELLS;
D O I
10.1016/j.mad.2012.05.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Telomere shortening, a well-known marker of aging and cellular stress, occurs under several conditions in the hematopoietic compartment, including aplastic anemia and following iatrogenic noxae. We decided to verify whether pathological telomere erosion also arises in restored Philadelphia-negative (Ph-negative) hematopoiesis following successful treatment of chronic myeloid leukemia (CML). Eighty-one CML patients in complete cytogenetic remission were compared to 76 age-matched healthy subjects. Myeloid cells of CML patients had shorter telomeres than controls (6521 bp vs 7233 bp, p < 0.001). This difference was specific for the myeloid compartment, since it was not observed in lymphoid cells (6774 bp vs 6909 bp, p = 0.620). Acquired Ph-negative cytogenetic abnormalities (p = 0.010), lack of complete molecular remission (p = 0.016) and age (p = 0.013) were independent predictors of telomere shortening. Telomere dynamics were assessed over a median follow-up period of 22 months. We. documented accelerated non-physiological ongoing telomere shortening in 17/59 CML patients (28%). Patients experiencing grade 2-4 hematological toxicity, during CML remission possessed significantly shorter telomeres compared to those lacking toxicity (p = 0.005 for any toxicity, p = 0.007 for anemia). CML patients suffer from significant and often ongoing telomere stress resulting in premature and selective aging of the myeloid compartment which might have long-term consequences on function and integrity of Ph-negative hematopoiesis. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:479 / 488
页数:10
相关论文
共 50 条
  • [21] Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments
    Sheng, Guangying
    Xue, Mengxing
    Wang, Qinrong
    Wen, Lijun
    Chen, Suning
    Zhang, Xinyou
    Yang, Xiaofei
    LEUKEMIA & LYMPHOMA, 2019, 60 (14) : 3503 - 3511
  • [22] Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
    Hijiya, Nobuko
    Mauro, Michael J.
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 873 - 891
  • [23] Treatment selection after imatinib resistance in chronic myeloid leukemia
    Jabbour, Elias
    Cortes, Jorge
    Kantarjian, Hagop
    TARGETED ONCOLOGY, 2009, 4 (01) : 3 - 10
  • [24] Successful Delivery after Planned Discontinuation of Imatinib in a Patient with Chronic Myeloid Leukemia
    Kobayashi, Kazuhiko
    Takebayashi, Chiaki
    Miyata, Satoko
    Narimatsu, Hiroto
    Kami, Masahiro
    INTERNAL MEDICINE, 2009, 48 (05) : 369 - 371
  • [25] Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia
    Wasilewska, Ewa M.
    Panasiuk, Barbara
    Gniot, Michal
    Sawicka, Anna
    Kozlowska, Katarzyna
    Lewandowski, Krzysztof
    Kloczko, Janusz
    Midro, Alina T.
    CANCER GENETICS, 2017, 216 : 1 - 9
  • [26] Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
    Yung, Yammy
    Lee, Emily
    Chu, Hiu-Tung
    Yip, Pui-Kwan
    Gill, Harinder
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (02) : 1 - 43
  • [27] Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib
    Loriaux, M
    Deininger, M
    LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2197 - 2203
  • [28] Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
    Jabbour, Elias
    Cortes, Jorge
    Kantarjian, Hagop
    CORE EVIDENCE, 2009, 4 : 207 - 213
  • [29] BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
    An, Xin
    Tiwari, Amit K.
    Sun, Yibo
    Ding, Pei-Rong
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    LEUKEMIA RESEARCH, 2010, 34 (10) : 1255 - 1268
  • [30] Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy
    Nakamura, Fumi
    Arai, Honoka
    Nannya, Yasuhito
    Ichikawa, Motoshi
    Furuichi, Shiho
    Nagasawa, Fusako
    Takahashi, Wataru
    Handa, Tomoyuki
    Nakamura, Yuko
    Tanaka, Hiroko
    Nakamura, Yuka
    Sasaki, Ko
    Miyano, Satoru
    Ogawa, Seishi
    Mitani, Kinuko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (06) : 936 - 940